Focus on national stockpiles
The Company’s initial focus is to develop and market biologic drugs for stockpiling by government agencies. This strategy can expand into co-developing innovative drugs with government partners. The company has also successfully implemented a program conducting contract drug development work and manufacturing for other organizations. Clients have included the Government of Canada and an Asian pharmaceutical company.
In order to seize this growing opportunity, AntoXa is seeking a Series A round of $5 million to advance product opportunities and later will offer a Series B round of $15 million to establish a Canadian manufacturing facility.
By using the vivoXPRESS® system and its own manufacturing facility, AntoXa will be able to produce affordable medical countermeasures at significantly lower costs compared to competitive products made in traditional mammalian cell culture systems.
AntoXa has the solution to a potentially deadly problem that, although impossible to predict, is almost certain to happen.